PATENT CLAIM ANALYSIS

Application Number: 15895894
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "013300"]

Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.

Claim (Index 37):
The method of  claim 29 , wherein the mammal has a tumor selected from the group consisting of: melanoma, a lung tumor, multiple myeloma, and breast cancer.

Metadata:
- Claim Count in Document: 154.0
- Percentile: 88.0
- Lexical Diversity: 1.52381
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12434598', '13447091', '11982738', '14142094', '12467170']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.9247871162989886
- 35 USC 102 Novelty (BERT): 0.5919114297090153
- Combined Prediction Score: 0.8914995476399913
- Mean Citation Score: 802.431426
- Max Citation Score: 863.71063
- Similarity Product: 454.1961844515265

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test